text_1: Therapeutics receiving accelerated approval encounter a lower frequency of post-marketing safety events
text_2: Design and Setting Cohort study of all novel therapeutics approved by the FDA between January 1, 2001, and December 31, 2010, followed up through February 28, 2017.